These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31158087)

  • 1. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
    Woods BS; Sideris E; Sydes MR; Gannon MR; Parmar MKB; Alzouebi M; Attard G; Birtle AJ; Brock S; Cathomas R; Chakraborti PR; Cook A; Cross WR; Dearnaley DP; Gale J; Gibbs S; Graham JD; Hughes R; Jones RJ; Laing R; Mason MD; Matheson D; McLaren DB; Millman R; O'Sullivan JM; Parikh O; Parker CC; Peedell C; Protheroe A; Ritchie AWS; Robinson A; Russell JM; Simms MS; Srihari NN; Srinivasan R; Staffurth JN; Sundar S; Thalmann GN; Tolan S; Tran ATH; Tsang D; Wagstaff J; James ND; Sculpher MJ
    Eur Urol Oncol; 2018 Dec; 1(6):449-458. PubMed ID: 31158087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
    James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
    Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
    Sathianathen NJ; Alarid-Escudero F; Kuntz KM; Lawrentschuk N; Bolton DM; Murphy DG; Kim SP; Konety BR
    Eur Urol Oncol; 2019 Nov; 2(6):649-655. PubMed ID: 31411985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
    Zhang P; Wen F; Fu P; Yang Y; Li Q
    Tumori; 2017 Jul; 103(4):380-386. PubMed ID: 28009424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
    Clarke CS; Hunter RM; Gabrio A; Brawley CD; Ingleby FC; Dearnaley DP; Matheson D; Attard G; Rush HL; Jones RJ; Cross W; Parker C; Russell JM; Millman R; Gillessen S; Malik Z; Lester JF; Wylie J; Clarke NW; Parmar MKB; Sydes MR; James ND
    PLoS One; 2022; 17(6):e0269192. PubMed ID: 35653395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
    Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
    Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
    Clarke NW; Ali A; Ingleby FC; Hoyle A; Amos CL; Attard G; Brawley CD; Calvert J; Chowdhury S; Cook A; Cross W; Dearnaley DP; Douis H; Gilbert D; Gillessen S; Jones RJ; Langley RE; MacNair A; Malik Z; Mason MD; Matheson D; Millman R; Parker CC; Ritchie AWS; Rush H; Russell JM; Brown J; Beesley S; Birtle A; Capaldi L; Gale J; Gibbs S; Lydon A; Nikapota A; Omlin A; O'Sullivan JM; Parikh O; Protheroe A; Rudman S; Srihari NN; Simms M; Tanguay JS; Tolan S; Wagstaff J; Wallace J; Wylie J; Zarkar A; Sydes MR; Parmar MKB; James ND
    Ann Oncol; 2019 Dec; 30(12):1992-2003. PubMed ID: 31560068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
    Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
    Sathianathen NJ; Lawrentschuk N; Konety B; Azad AA; Corcoran NM; Bolton DM; Murphy DG
    Eur Urol Oncol; 2024 Aug; 7(4):870-876. PubMed ID: 38057191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
    Vale CL; Burdett S; Rydzewska LHM; Albiges L; Clarke NW; Fisher D; Fizazi K; Gravis G; James ND; Mason MD; Parmar MKB; Sweeney CJ; Sydes MR; Tombal B; Tierney JF;
    Lancet Oncol; 2016 Feb; 17(2):243-256. PubMed ID: 26718929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
    Collins R; Fenwick E; Trowman R; Perard R; Norman G; Light K; Birtle A; Palmer S; Riemsma R
    Health Technol Assess; 2007 Jan; 11(2):iii-iv, xv-xviii, 1-179. PubMed ID: 17181985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
    Ramamurthy C; Handorf EA; Correa AF; Beck JR; Geynisman DM
    Urol Oncol; 2019 Oct; 37(10):688-695. PubMed ID: 31399302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
    Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
    James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
    Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.